The complex group of opioid receptors are biologically and clinically important in mediating the action of endogenous and exogenous opioids. Despite the clinical advantages of developing drugs which serve as specific agonists and antagonists for opioid receptor subtypes, studies to date have been limited by the inability to satisfactorily isolate and characterize these multiple opioid receptors. This project is aimed at better defining the biochemical and molecular basis of opioid systems and actions. The opioid receptor system is believed to consist of at least an opioid ligand binding receptor protein, and an inhibitory guanine nucleotide regulatory system (Gi) which regulates the receptor affinity and possibly serves as a signal transducer to produce cellular biochemical responses such as inhibition of adenylate cyclase and of neurotransmitter release. Based on this model, we plan to define the role of Gi in the opioid receptor system. We have successfully purified substantial quantities of Gi from rat brains. We propose to further characterize this Gi protein, to reconstitute Gi back to membranes containing """"""""uncoupled"""""""" opioid receptors, to use this Gi as a tool to purify solubilized opioid receptors, and to study possible mechanisms of tolerance that involve Gi. We have recently established a rat spinal tolerance model where we can manipulate to achieve selective as well as cross tolerance to specific Mu- and Delta-agonists. The Mu- and Delta-receptor binding activities and opioid sensitive GTPase activity will be examined in these spinal cord membranes to correlate with the development of opioid tolerance. The spinal membranes from tolerant animals will also be used in reconstitution experiments to study the role of G-proteins in opioid tolerance. As shown in the Preliminary Studies we have isolated a large quantity of Gi- and Go-protein from rat brains. We will attempt to further separate Go and Gi and to study their individual roles in the opioid receptor systems. Information generated from these studies will add to the elucidation of the molecular basis of the opioid receptor system and the mechanism of opioid actions.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004240-02
Application #
3209618
Study Section
(DABB)
Project Start
1986-09-01
Project End
1989-08-31
Budget Start
1987-09-01
Budget End
1988-08-31
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Su, Y F; McNutt, R W; Chang, K J (1998) Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J Pharmacol Exp Ther 287:815-23
Li, L Y; Chang, K J (1996) The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors. Mol Pharmacol 50:599-602
Wong, C S; Su, Y F; Watkins, W D et al. (1994) Opioid agonist binding affinity is increased by magnesium in the presence of guanosine diphosphate but decreased by magnesium in the presence of guanyl-5'-yl imidodiphosphate. J Pharmacol Exp Ther 268:653-61
Li, L Y; Su, Y F; Zhang, Z M et al. (1993) Purification and cloning of opioid receptors. NIDA Res Monogr 134:146-64
Li, L Y; Zhang, Z M; Su, Y F et al. (1992) Purification of opioid receptor in the presence of sodium ions. Life Sci 51:1177-85
Wong, C S; Su, Y F; Chang, K J et al. (1992) Intrathecal pertussis toxin treatment attenuates opioid antinociception and reduces high-affinity state of opioid receptors. Anesthesiology 77:691-9
Wong, C S; Su, Y F; Watkins, W D et al. (1992) Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes. J Pharmacol Exp Ther 262:317-26
Nishino, K; Su, Y F; Wong, C S et al. (1990) Dissociation of mu opioid tolerance from receptor down-regulation in rat spinal cord. J Pharmacol Exp Ther 253:67-72
Russell, R D; Chang, K J (1989) Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance. Pain 36:381-9